Neuland Laboratories (NEULANDLAB.NS) Stock Price

Neuland Laboratories Price

NSE·CLOSED
22,855.00INR+1,312.00 (+5.91 %)
Market closed

Over the last 18 years Neuland Laboratories grew revenue by 11.7% annually, reaching 14.77 B INR. Earnings per share have grown at 16.1% per year over the last 18 years. For Neuland Laboratories, the net margin of 17.6% is up versus 8.6% a few years ago. At today's price the dividend yield works out to roughly 0.05%. The payout ratio is around 6% of earnings. The dividend has grown at 11.6% per year over the past 18 years. The consensus 12-month price target for Neuland Laboratories is 19,023.00 INR, about 16.8% below where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 99% above its 52-week low.

Neuland Laboratories stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Neuland Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neuland Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neuland Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Neuland Laboratories Stock Price History
DateNeuland Laboratories Price
8/7/202622,855.00 INR
8/6/202621,543.00 INR
8/5/202619,956.00 INR
8/4/202619,430.00 INR
7/31/202619,043.00 INR
7/30/202619,306.00 INR
7/28/202618,829.00 INR
7/24/202618,546.00 INR
7/23/202618,431.00 INR
7/22/202618,466.00 INR
7/21/202618,895.00 INR
7/20/202618,949.00 INR
7/17/202618,434.00 INR
7/16/202618,751.00 INR
7/15/202619,114.00 INR
7/14/202618,999.00 INR
7/13/202619,019.00 INR
7/10/202619,506.00 INR
7/9/202619,542.00 INR
7/8/202618,889.00 INR
7/7/202618,900.00 INR
7/6/202618,956.00 INR
7/3/202618,949.00 INR
7/2/202618,988.00 INR
7/1/202618,786.00 INR
6/30/202618,579.00 INR
6/29/202618,088.00 INR
6/25/202617,961.00 INR
6/24/202618,072.00 INR
6/23/202618,102.00 INR
6/22/202617,224.00 INR
6/19/202617,352.00 INR
6/18/202617,028.00 INR
6/17/202616,940.00 INR
6/16/202617,131.00 INR
6/15/202617,271.00 INR
6/12/202617,175.00 INR
6/11/202616,913.00 INR
6/10/202616,990.00 INR
6/9/202617,188.00 INR
6/8/202616,964.00 INR
6/5/202616,974.00 INR
6/4/202616,742.00 INR
6/3/202616,992.00 INR
6/2/202616,909.00 INR
6/1/202616,920.00 INR
5/29/202617,003.00 INR
5/27/202617,280.00 INR
5/26/202617,152.00 INR
5/25/202616,840.00 INR
5/22/202617,040.00 INR
5/21/202616,766.00 INR
5/20/202616,932.00 INR
5/19/202616,790.00 INR
5/18/202616,327.00 INR
5/15/202616,590.00 INR
5/14/202616,680.00 INR
5/13/202616,497.00 INR
5/12/202617,003.00 INR
5/11/202617,550.00 INR
5/8/202617,666.00 INR
5/7/202617,285.00 INR
5/6/202617,032.00 INR
5/5/202616,204.00 INR
5/4/202616,124.00 INR
5/1/202615,003.00 INR
4/30/202615,003.00 INR
4/29/202614,656.00 INR
4/28/202614,445.00 INR
4/27/202614,755.00 INR
4/24/202614,405.00 INR
4/23/202614,977.00 INR
4/22/202615,067.00 INR
4/21/202614,920.00 INR
4/20/202615,202.00 INR
4/17/202615,295.00 INR
4/16/202615,000.00 INR
4/15/202614,982.00 INR
4/13/202614,512.00 INR
4/10/202614,951.00 INR
4/9/202614,723.00 INR
4/8/202614,055.00 INR
4/7/202613,176.00 INR
4/6/202613,222.00 INR
4/2/202612,433.00 INR
4/1/202612,613.00 INR
3/30/202612,027.00 INR
3/27/202612,067.00 INR
3/25/202612,099.00 INR
3/24/202612,002.00 INR
3/23/202611,500.00 INR
3/20/202612,001.00 INR
3/19/202612,115.00 INR
3/18/202612,395.00 INR
3/17/202612,299.00 INR
3/16/202612,330.00 INR
3/13/202612,150.00 INR
3/12/202612,590.00 INR
3/11/202612,838.00 INR
3/10/202612,598.00 INR
3/9/202612,601.00 INR
3/6/202613,050.00 INR
3/5/202612,945.00 INR
3/4/202612,720.00 INR
3/2/202613,109.00 INR
2/27/202612,910.00 INR
2/26/202613,180.00 INR
2/25/202613,366.00 INR
2/24/202613,400.00 INR
2/23/202613,507.00 INR
2/20/202612,650.00 INR
2/19/202613,020.00 INR
2/18/202613,649.00 INR
2/17/202613,640.00 INR
2/16/202613,296.00 INR
2/13/202613,044.00 INR
2/12/202612,950.00 INR
2/11/202613,200.00 INR
2/10/202613,450.00 INR
2/9/202613,895.00 INR
2/6/202612,999.00 INR
2/5/202613,185.00 INR
2/4/202613,480.00 INR
2/3/202613,403.00 INR
2/2/202613,166.00 INR
2/1/202613,450.00 INR
1/30/202613,213.00 INR
1/29/202612,502.00 INR
1/28/202612,846.00 INR
1/27/202612,800.00 INR
1/23/202613,425.00 INR
1/22/202613,521.00 INR
1/21/202613,265.00 INR
1/20/202613,590.00 INR
1/19/202613,880.00 INR
1/16/202614,051.00 INR
1/14/202614,299.00 INR
1/13/202614,297.00 INR
1/12/202614,620.00 INR
1/9/202614,752.00 INR
1/8/202614,765.00 INR
1/7/202615,139.00 INR
1/6/202614,490.00 INR
1/5/202615,030.00 INR
1/2/202615,282.00 INR
1/1/202615,045.00 INR
12/31/202515,210.00 INR
12/30/202515,000.00 INR
12/29/202515,000.00 INR
12/26/202515,200.00 INR
12/24/202515,052.00 INR
12/23/202515,300.00 INR
12/22/202515,779.00 INR
12/19/202515,970.00 INR
12/18/202515,840.00 INR
12/17/202515,740.00 INR
12/16/202516,150.00 INR
12/15/202516,525.00 INR
12/12/202516,100.00 INR
12/11/202516,285.00 INR
12/10/202516,310.00 INR
12/9/202516,550.00 INR
12/8/202516,065.00 INR
12/5/202516,805.00 INR
12/4/202516,935.00 INR
12/3/202516,932.00 INR
12/2/202516,369.00 INR
12/1/202516,555.00 INR
11/28/202517,190.00 INR
11/27/202516,566.00 INR
11/26/202516,601.00 INR
11/25/202516,738.00 INR
11/24/202516,299.00 INR
11/21/202516,547.00 INR
11/20/202516,739.00 INR
11/19/202517,041.00 INR
11/18/202517,279.00 INR
11/17/202517,360.00 INR
11/14/202517,401.00 INR
11/13/202517,235.00 INR
11/12/202517,530.00 INR
11/11/202517,149.00 INR
11/10/202518,026.00 INR
11/7/202517,767.00 INR
11/6/202517,520.00 INR
11/4/202517,618.00 INR
11/3/202517,166.00 INR
10/31/202516,552.00 INR
10/30/202516,170.00 INR
10/29/202515,420.00 INR
10/28/202515,800.00 INR
10/27/202515,722.00 INR
10/24/202515,991.00 INR
10/23/202516,160.00 INR
10/21/202516,209.00 INR
10/20/202516,410.00 INR
10/17/202516,260.00 INR
10/16/202516,152.00 INR
10/15/202516,100.00 INR
10/14/202516,220.00 INR
10/13/202516,215.00 INR
10/10/202516,310.00 INR
10/9/202515,690.00 INR
10/8/202515,466.00 INR
10/7/202515,750.00 INR
10/6/202515,106.00 INR
10/3/202515,196.00 INR
10/1/202515,398.00 INR
9/30/202514,600.00 INR
9/29/202514,500.00 INR
9/26/202513,969.00 INR
9/25/202514,877.00 INR
9/24/202514,962.00 INR
9/23/202515,110.00 INR
9/22/202515,311.00 INR
9/19/202515,400.00 INR
9/18/202515,853.00 INR
9/17/202516,200.00 INR
9/16/202516,135.00 INR
9/15/202515,696.00 INR
9/12/202515,960.00 INR
9/11/202515,565.00 INR
9/10/202514,795.00 INR
9/9/202514,418.00 INR
9/8/202514,450.00 INR
9/5/202514,549.00 INR
9/4/202514,600.00 INR
9/3/202514,500.00 INR
9/2/202513,729.00 INR
9/1/202513,399.00 INR
8/29/202513,390.00 INR
8/28/202513,190.00 INR
8/26/202513,170.00 INR
8/25/202513,500.00 INR
8/22/202513,850.00 INR
8/21/202513,740.00 INR
8/20/202513,600.00 INR
8/19/202513,051.00 INR
8/18/202513,500.00 INR
8/14/202513,254.00 INR
8/13/202513,005.00 INR
8/12/202512,948.00 INR
Access this data via the Eulerpool API
Get Free API Key

Neuland Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
9.51 B INR
957.53 M INR
638.22 M INR
Jan 1, 2023
11.91 B INR
2.31 B INR
1.64 B INR
Jan 1, 2024
15.59 B INR
4.28 B INR
3.00 B INR
Jan 1, 2025
14.77 B INR
2.67 B INR
2.60 B INR
Jan 1, 2026 (e)
17.64 B INR
3.76 B INR
2.57 B INR
Jan 1, 2027 (e)
23.09 B INR
4.92 B INR
4.19 B INR
Jan 1, 2028 (e)
27.80 B INR
5.92 B INR
5.84 B INR
Jan 1, 2029 (e)
33.15 B INR
7.06 B INR
6.74 B INR

Neuland Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:57 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
4.664.655.105.885.296.677.639.379.5111.9115.5914.7717.6423.0927.8033.15
1.11-0.199.7315.26-9.9726.0314.3822.841.5025.2630.83-5.2419.4330.9120.4019.25
39.1338.7141.7943.4241.5635.9340.6743.2244.5649.1555.0151.3951.3951.3951.3951.39
1.821.802.132.552.202.403.104.054.245.868.577.599.0611.8614.2817.03
0.620.500.650.880.290.380.721.100.962.314.282.673.764.925.927.06
13.2110.8012.6915.015.485.679.4711.6910.0619.3527.4418.0521.3021.3121.3021.30
0.270.160.270.470.120.160.160.810.641.643.002.602.574.195.846.74
94.20-40.6771.7071.43-74.3636.67-1.22397.53-20.84156.2783.49-13.30-1.1963.1139.2215.47
1.501.502.002.00–1.204.004.006.0010.0014.0012.0012.0014.4017.28–
25.00–33.33–––233.33–50.0066.6740.00-14.29–20.0020.00–
8.308.508.9011.2011.2012.6012.8012.8012.8312.8312.8312.8312.8312.8312.8312.83
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Neuland Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neuland Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neuland Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Neuland Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neuland Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Neuland Laboratories stock margins

The Neuland Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neuland Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neuland Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
43.22 %
11.70 %
8.61 %
Jan 1, 2022
44.56 %
10.07 %
6.71 %
Jan 1, 2023
49.16 %
19.36 %
13.73 %
Jan 1, 2024
55.01 %
27.44 %
19.25 %
Jan 1, 2025
51.39 %
18.05 %
17.61 %
Jan 1, 2026 (e)
51.39 %
21.31 %
14.57 %
Jan 1, 2027 (e)
51.39 %
21.31 %
18.16 %
Jan 1, 2028 (e)
51.39 %
21.31 %
21.00 %

Neuland Laboratories Stock Revenue, EBIT, Earnings per Share

The Neuland Laboratories earnings per share therefore indicates how much revenue Neuland Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
731.96 INR
85.61 INR
62.99 INR
Jan 1, 2022
741.30 INR
74.63 INR
49.74 INR
Jan 1, 2023
928.45 INR
179.72 INR
127.45 INR
Jan 1, 2024
1,214.80 INR
333.35 INR
233.89 INR
Jan 1, 2025
1,151.12 INR
207.78 INR
202.74 INR
Jan 1, 2026 (e)
1,374.72 INR
292.91 INR
200.31 INR
Jan 1, 2027 (e)
1,799.55 INR
383.43 INR
326.80 INR
Jan 1, 2028 (e)
2,166.70 INR
461.66 INR
454.92 INR

Neuland Laboratories business model & stock analysis

Neuland Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Neuland Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Neuland Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Neuland Laboratories shares outstanding

The number of shares of Neuland Laboratories was 12.83 M in 2025. This indicates how many shares Neuland Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
12.80 M Stocks
Jan 1, 2022
12.83 M Stocks
Jan 1, 2023
12.83 M Stocks
Jan 1, 2024
12.83 M Stocks
Jan 1, 2025
12.83 M Stocks
Jan 1, 2026 (e)
12.83 M Stocks
Jan 1, 2027 (e)
12.83 M Stocks
Jan 1, 2028 (e)
12.83 M Stocks

Neuland Laboratories Dividend History

26 years of dividend payments

YearAnnual DividendYoY ChangePayments
202512.00INR↓ 14.3%1×
Jul 18, 202512.00INR↓ 14.3%1/1
202414.00INR↑ 40.0%1×
202310.00INR↑ 100.0%1×
20225.00INR↑ 66.7%1×
20213.00INR↓ 25.0%1×
20204.00INR↑ 233.3%2×
20191.20INR↓ 40.0%1×
20172.00INR 0.0%—
20162.00INR↑ 33.3%1×
20151.50INR 0.0%1×

Neuland Laboratories dividend history and estimates

In 2025, Neuland Laboratories paid a dividend amounting to 12.00 INR. Dividend means that Neuland Laboratories distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
3.00 INR
1.00 INR
Jan 1, 2022 (e)
5.00 INR
1.00 INR
Jan 1, 2023
10.00 INR
0.00 INR
Jan 1, 2024
14.00 INR
0.00 INR
Jan 1, 2025
12.00 INR
0.00 INR
Jan 1, 2026
12.00 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
14.40 INR
Jan 1, 2028 (e)
0.00 INR
17.28 INR

Neuland Laboratories dividend payout ratio

In 2025, Neuland Laboratories had a payout ratio of 5.92%. The payout ratio indicates the percentage of the company's profits that Neuland Laboratories distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
4.76 %
Jan 1, 2022
10.05 %
Jan 1, 2023
7.85 %
Jan 1, 2024
5.99 %
Jan 1, 2025
5.92 %
Jan 1, 2026 (e)
5.99 %
Jan 1, 2027 (e)
4.41 %
Jan 1, 2028 (e)
3.80 %

Current Neuland Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
14.08 %
Buy
90.00 % (9)
Hold
10.00 % (1)
Sell
0.00 % (0)
12M Price Target
19,023.00
Last Price
22,216.00
Currency
INR
12M Return Potential
-14.37 %
LTM Return
0 %

Neuland Laboratories shareholder structure

% Name
25.98092%
Davuluri Ownership Trust
Davuluri Ownership Trust
5.69186%
Malabar Investment Advisors Private Limited
Malabar Investment Advisors Private Limited
3.11769%
Agrawal (Mukul Mahavirprasad)
Agrawal (Mukul Mahavirprasad)
2.88271%
ICICI Prudential Asset Management Co. Ltd.
ICICI Prudential Asset Management Co. Ltd.
2.05581%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.01067%
Davuluri (Sucheth Rao)
Davuluri (Sucheth Rao)
...

Neuland Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
55.6%
Float Shares
-
Shares Outstanding
-

Neuland Laboratories Executives and Management Board

13 members · avg. age 70 · 15 % women

DR

Mr. Davuluri Rao

Chief Executive Officer, Whole Time Vice Chairman of the Board · since 2016

30.00 M INR

Management

DR

Mr. Davuluri Rao

Whole Time Vice Chairman of the Board, Joint Managing Director

30.00 M INR
AM

Mr. Abhijit Majumdar

Chief Financial Officer

–
SK

Dr. Sharadsrikar Kotturi

Chief Scientific Officer

–
SB

Ms. Sarada Bhamidipati

Compliance Officer, Company Secretary

–
AS

Mr. Ashutosh Sinha

Chief Quality Officer

–
DP

Mr. Diwakar Pingle

Managing Director

–

Board of Directors

DR

Dr. Davuluri Rao

Executive Chairman of the Board · since 2021

33.00 M INR
HK

Mr. Homi Khusrokhan

Non-Executive Independent Director

1.03 M INR
PB

Ms. Pallavi Bhakru

Additional Independent Director

–
RG

Dr. Ravi Gopinath (60)

Additional Independent Director

–
PM

Mr. Prasad Menon (79)

Additional Independent Director

–
SS

Mr. Sugata Sircar

Additional Independent Director

–

Frequently asked questions about Neuland Laboratories

Analysts currently set an average price target of 19,756.13 INR for the Neuland Laboratories stock (median: 19,023.00 INR), implying -11.1 % versus the latest price. The consensus is based on 10 analyst ratings.

Neuland Laboratories Analyst Price Targets 2026

10 analysts currently rate the Neuland Laboratories stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuland Laboratories to generate revenue of 17.64 B INR and earnings per share of 200.32 INR.

Neuland Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Neuland Laboratories share trades at 207.63 EUR (22,855.00 INR).

No history available for Neuland Laboratories.

The expected revenue of Neuland Laboratories is 17.64 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Neuland Laboratories is 2.57 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neuland Laboratories is currently 114.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuland Laboratories stock.

The price-to-sales ratio (P/S) of Neuland Laboratories is currently 16.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuland Laboratories stock.

The Eulerpool Quality Score for Neuland Laboratories is 7/10.

The ISIN of Neuland Laboratories is INE794A01010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Neuland Laboratories is NEULANDLAB.NS. The ticker symbol is used to trade Neuland Laboratories shares on the stock exchange.

Over the past 12 months, Neuland Laboratories paid a dividend of 12.00 INR . This corresponds to a dividend yield of about 0.05 %. For the coming 12 months, Neuland Laboratories is expected to pay a dividend of 14.40 INR.

The current dividend yield of Neuland Laboratories is 0.05 %.

Neuland Laboratories pays a dividend, distributed in the months of , , , .

Neuland Laboratories paid dividends every year for the past 7 years.

For the upcoming 12 months, dividends amounting to 14.40 INR are expected. This corresponds to a dividend yield of 0.06 %.

Neuland Laboratories is assigned to the 'Health' sector.

To receive the latest dividend of Neuland Laboratories from amounting to 12 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Neuland Laboratories distributed 10 INR as dividends.

The dividends of Neuland Laboratories are distributed in INR.

All fundamentals and in-depth analysis of Neuland Laboratories

Our stock analysis for Neuland Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuland Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Neuland Laboratories Stock
Neuland Laboratories Revenue→
Neuland Laboratories Stock
Neuland Laboratories Net Income→
Neuland Laboratories Stock
Neuland Laboratories P/E→
Neuland Laboratories Stock
Neuland Laboratories P/S→
Neuland Laboratories Stock
Neuland Laboratories EBIT→
Neuland Laboratories Stock
Neuland Laboratories Dividend→
Neuland Laboratories Stock
Neuland Laboratories Directors Dealings→
Neuland Laboratories Stock
Neuland Laboratories Stocks→
Neuland Laboratories Stock
Neuland Laboratories Market capitalization→
Neuland Laboratories Stock
Neuland Laboratories Debt→
Neuland Laboratories Stock
Neuland Laboratories Liabilities→
Neuland Laboratories Stock
Neuland Laboratories Equity→
Neuland Laboratories Stock
Neuland Laboratories AAQS→
Neuland Laboratories Stock
Neuland Laboratories Employees→
Neuland Laboratories Stock
Neuland Laboratories ROE→
Neuland Laboratories Stock
Neuland Laboratories ROA→
Neuland Laboratories Stock
Neuland Laboratories ROCE→
Neuland Laboratories Stock
Neuland Laboratories News→
Neuland Laboratories Stock
Neuland Laboratories Analyst Price Targets→

Health Stocks

Neumora TherapeuticsNeucaNeuPath HealthNetraMark HoldingsNeuphoria TherapeuticsNetcareNeuraxisNet Medical Xpress SolutionsNeuren PharmaceuticalsNestmedicNeurizon TherapeuticsNephro Care IndiaAll Stocks A–Z →